• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    France Depression Screening Mental Health Market

    ID: MRFR/HC/54519-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    France Depression Screening Mental Health Market Research Report By Indication (Major Depressive Disorder, Anxiety Distress, Bipolar Disorder, Psychotic Disorders, Others), By Diagnosis (Psychological Tests, Blood Tests, Pharmacogenomic Testing, Others) and By End User (Hospitals and Clinics, Home-based, Research and Academic Institutes)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    France Depression Screening Mental Health Market Research Report - Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    France Depression Screening Mental Health Market Summary

    The France Depression Screening Mental Health market is projected to grow significantly from 31.0 USD Million in 2024 to 93.2 USD Million by 2035.

    Key Market Trends & Highlights

    France Depression Screening Mental Health Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 10.51% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 93.2 USD Million, indicating robust growth potential.
    • In 2024, the market is valued at 31.0 USD Million, reflecting the current demand for depression screening solutions in France.
    • Growing adoption of digital health technologies due to increased awareness of mental health issues is a major market driver.

    Market Size & Forecast

    2024 Market Size 31.0 (USD Million)
    2035 Market Size 93.2 (USD Million)
    CAGR (2025-2035) 10.51%

    Major Players

    Pfizer, Ipsen, GSK, Teva Pharmaceuticals, Otsuka, Servier, H Lundbeck, Sanofi, AstraZeneca, Roche, Almirall, Bristol Myers Squibb, Novartis, Lilly, Johnson & Johnson

    France Depression Screening Mental Health Market Trends

    Moreover, advancements in technology are transforming the landscape of depression screening.With the rise of telehealth services, particularly post-COVID-19, patients can now access mental health screenings from the comfort of their homes. This trend has broadened opportunities for those who might otherwise hesitate to seek help in traditional settings. Similarly, mobile health applications have emerged as valuable tools for self-assessment, enabling users to monitor their mental health regularly and seek help proactively. There are also significant opportunities for collaboration between healthcare providers and technology companies to develop innovative screening tools tailored the French population. 

    France Depression Screening Mental Health Market Drivers

    Market Segment Insights

    France Depression Screening Mental Health Market Segment Insights

    France Depression Screening Mental Health Market Segment Insights

    Depression Screening Mental Health Market Indication Insights

    Depression Screening Mental Health Market Indication Insights

    The France Depression Screening Mental Health Market has become increasingly important due to rising mental health awareness and the growing need for effective screening methods. Within this market, the Indication segment plays a crucial role in identifying various mental health conditions. Major Depressive Disorder remains a significant aspect of this segment as it is one of the most prevalent mental health issues affecting individuals across different age groups in France. The timely identification of this disorder is essential for early intervention and treatment, which can significantly improvequality of life.

    Additionally, Anxiety Distress has gained attention due to its rising incidence, with many individuals experiencing anxiety, particularly in high-pressure environments.

    This segment's focus on anxiety-related disorders underscores the need for comprehensive screening approaches, aligning with the broader mental health initiatives of health authorities in France.Further, Bipolar Disorder continues to be a noteworthy condition within the Indication segment, characterized by its unique patterns of mood changes that can complicate the diagnosis and treatment process. The complexity of this disorder highlights the importance of sophisticated screening tools to assist healthcare providers in delivering effective care. Psychotic Disorders are another critical aspect, requiring distinct evaluation and monitoring strategies to ensure that affected individuals receive appropriate interventions.

    The prevalence of such disorders in the population necessitates the availability of standardized screening methods to facilitate accurate diagnosis and timely treatment. Lastly, the category labeled Others encompasses a variety of mental health conditions, reflecting the diversity within the population and the necessity for tailored screening methods that address the broader spectrum of mental health challenges. The collaborative efforts of the French health system, coupled with the increasing recognition of mental health issues, create opportunities for advancements in screening methodologies, ultimately contributing to improved outcomes for individuals facing such challenges.

    Depression Screening Mental Health Market Diagnosis Insights

    Depression Screening Mental Health Market Diagnosis Insights

    The Diagnosis segment within the France Depression Screening Mental Health Market plays a crucial role in identifying and managing depression among the population. This segment encompasses various methods, including Psychological Tests, Blood Tests, Pharmacogenomic Testing, and Others, reflecting a diverse approach to mental health assessment. Psychological Tests are important as they facilitate the evaluation of emotional and psychological states, providing valuable insights into an individual's mental health. Blood Tests contribute significantly by identifying biological markers linked to depression, enabling healthcare professionals to make more informed decisions about treatment options.

    Pharmacogenomic Testing holds great importance as it assesses how genetic variations affect an individual's response to medications, thus optimizing treatment plans. The emphasis on these diagnostic tools is largely driven by the increasing prevalence of depression in France, prompting a greater need for accurate and timely diagnosis to improve patient outcomes. This market segment is characterized by ongoing advancements in technology and research, creating new opportunities for innovative testing methods and personalized treatment strategies that are vital in addressing mental health challenges effectively.

    Depression Screening Mental Health Market End User Insights

    Depression Screening Mental Health Market End User Insights

    The End User segment of the France Depression Screening Mental Health Market plays a crucial role in addressing the pressing mental health needs of the population. Hospitals and clinics are at the forefront, providing comprehensive screening and treatment services, thus ensuring timely intervention for those suffering from depression. This segment is vital as it allows for an integrated approach to mental health care, combining medical and psychological expertise under one roof.

    Home-based care is becoming increasingly significant, offering flexibility and accessibility to patients who may have mobility challenges or prefer receiving care in the comfort of their homes.This trend aligns with France’s commitment to promoting mental well-being and improving access to mental health resources. 

    Research and academic institutions are equally essential, driving innovation and developing new screening tools and methodologies, ultimately enhancing the effectiveness of depression detection within the healthcare system. The emphasis on these various End Users is evident in national health policies aimed at reducing the stigma associated with mental health treatment and fostering supportive environments for those seeking help.Overall, these segments collectively contribute to a more robust mental health framework in France, focusing on increased awareness, better diagnosis, and effective treatment pathways.

    Get more detailed insights about France Depression Screening Mental Health Market Research Report - Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The France Depression Screening Mental Health Market is characterized by an evolving landscape shaped significantly by an increasing awareness of mental health issues and the importance of early diagnosis and intervention. The competitive dynamics within this market reveal a growing emphasis on innovative screening solutions, digital therapeutics, and collaborative care models designed to enhance patient outcomes. Companies are continuously exploring avenues to develop more refined screening tools to improve accuracy and accessibility, thereby catering to a diverse population burdened with depression. 

    The market is witnessing a strategic focus on partnerships and collaborations aimed at driving research, integrating technology, and enhancing service delivery in mental health care, reflecting the necessity for comprehensive approaches to tackle depression effectively.Pfizer has established a notable presence in the France Depression Screening Mental Health Market, driven by its strong capabilities in pharmaceutical development and a commitment to mental health. The company's strengths lie in its rigorous research and development processes, which have ensured a consistent pipeline of innovative mental health solutions targeted specifically at depression.

    Pfizer's extensive distribution networks and partnerships within the healthcare ecosystem in France enable it to reach a wide range of stakeholders, from healthcare professionals to patients. 

    The company also focuses on educational initiatives that foster a better understanding of depression and the significance of screening, which supports its brand positioning as a leader in mental health advocacy. Pfizer’s established reputation in the pharmaceutical sector provides it with a competitive edge, enhancing its ability to introduce effective solutions for depression screening in France.Ipsen is another key player in the France Depression Screening Mental Health Market, recognized for its targeted approach to mental health solutions. The company focuses on the development and delivery of innovative therapies that are effective in managing various mental health conditions, including depression.

    Ipsen's strengths include a solid commitment to research and development, with ongoing efforts to expand its portfolio through mergers and acquisitions that align with its strategic vision in mental health. 

    By establishing collaborations with local healthcare providers and research institutions, Ipsen enhances its market presence and deepens its understanding of regional needs. In terms of key products, Ipsen offers therapies that address the neurobiological aspects of depression, showcasing its dedication to advancing treatment options. The company's focus on personalized care and a patient-centric approach has solidified its reputation in the French market, enabling it to effectively compete and respond to the growing demand for mental health solutions.

    Key Companies in the France Depression Screening Mental Health Market market include

    Industry Developments

    In the France Depression Screening Mental Health Market, recent developments have indicated a significant uptick in investments and innovations aimed at enhancing mental health services. Notably, companies like GSK and AstraZeneca have ramped up their efforts in developing digital solutions for depression screening, in line with increasing governmental support for mental health initiatives since 2021. Additionally, in August 2023, Pfizer announced a collaboration with a French tech firm to leverage artificial intelligence in early detection and intervention strategies, marking a proactive approach addressing mental health challenges among the French population. 

    Merger activity has also been notable, with Teva Pharmaceuticals acquiring a regional competitor in April 2023, further consolidating its position in the mental health sector. The French government's 2022 policy reforms emphasizing mental health have spurred growth within the industry, resulting in increased market valuation for significant players, including Sanofi and Roche. As of September 2023, various reports indicate that the market is experiencing an annual growth rate of approximately 5%, driven by both technological advancements and a greater societal focus on mental healthcare awareness.

    Market Segmentation

    Outlook

    • Hospitals and Clinics
    • Home-based
    • Research and Academic Institutes

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 31.03(USD Million)
    MARKET SIZE 2024 45.27(USD Million)
    MARKET SIZE 2035 93.15(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 6.78% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Pfizer, Ipsen, GSK, Teva Pharmaceuticals, Otsuka, Servier, H Lundbeck, Sanofi, AstraZeneca, Roche, Almirall, Bristol Myers Squibb, Novartis, Lilly, Johnson & Johnson
    SEGMENTS COVERED Indication, Diagnosis, End User
    KEY MARKET OPPORTUNITIES Increasing telehealth adoption, Rising awareness campaigns, Innovative screening technologies, Integration of AI solutions, Expanding mental health policies
    KEY MARKET DYNAMICS rising mental health awareness, increasing healthcare access, technological advancements in screening, government support initiatives, growing prevalence of depression
    COUNTRIES COVERED France

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the projected market size of the France Depression Screening Mental Health Market in 2024?

    The projected market size of the France Depression Screening Mental Health Market in 2024 is expected to be valued at 45.27 million USD.

    What will the France Depression Screening Mental Health Market be valued at in 2035?

    By 2035, the France Depression Screening Mental Health Market is expected to reach a valuation of 93.15 million USD.

    What is the expected CAGR for the France Depression Screening Mental Health Market from 2025 to 2035?

    The expected CAGR for the France Depression Screening Mental Health Market from 2025 to 2035 is 6.78%.

    Which segment is projected to have the largest value in the France Depression Screening Mental Health Market in 2035?

    The Major Depressive Disorder segment is projected to have the largest value, estimated at 37.5 million USD in 2035.

    How much is the Anxiety Distress segment expected to be valued at in 2035?

    The Anxiety Distress segment is expected to be valued at 22.0 million USD in 2035.

    What is the estimated market size for the Bipolar Disorder segment in 2024?

    The Bipolar Disorder segment is estimated to be valued at 6.0 million USD in 2024.

    Who are the key players in the France Depression Screening Mental Health Market?

    Key players include Pfizer, GSK, AstraZeneca, Roche, and Sanofi among others.

    What is the market size for Psychotic Disorders in 2035?

    The market size for Psychotic Disorders is projected to be 9.45 million USD in 2035.

    How much revenue is expected from the Others segment in 2025?

    The Others segment is expected to contribute significantly, with a projected value reaching 12.2 million USD by 2035.

    What are some of the growth drivers for the France Depression Screening Mental Health Market?

    Key growth drivers include increasing awareness of mental health and rising prevalence of depression-related disorders.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. France
    59. Depression Screening Mental Health Market, BY Indication (USD Million)
    60. Major
    61. Depressive Disorder
    62. Anxiety Distress
    63. Bipolar
    64. Disorder
    65. Psychotic Disorders
    66. Others
    67. France
    68. Depression Screening Mental Health Market, BY Diagnosis (USD Million)
    69. Psychological
    70. Tests
    71. Blood Tests
    72. Pharmacogenomic
    73. Testing
    74. Others
    75. France
    76. Depression Screening Mental Health Market, BY End User (USD Million)
    77. Hospitals
    78. and Clinics
    79. Home-based
    80. Research
    81. and Academic Institutes
    82. Competitive Landscape
    83. Overview
    84. Competitive
    85. Analysis
    86. Market share Analysis
    87. Major
    88. Growth Strategy in the Depression Screening Mental Health Market
    89. Competitive
    90. Benchmarking
    91. Leading Players in Terms of Number of Developments
    92. in the Depression Screening Mental Health Market
    93. Key
    94. developments and growth strategies
    95. New Product Launch/Service
    96. Deployment
    97. Merger & Acquisitions
    98. Joint
    99. Ventures
    100. Major Players Financial Matrix
    101. Sales
    102. and Operating Income
    103. Major Players R&D Expenditure.
    104. Company
    105. Profiles
    106. Pfizer
    107. Financial
    108. Overview
    109. Products Offered
    110. Key
    111. Developments
    112. SWOT Analysis
    113. Key
    114. Strategies
    115. Ipsen
    116. Financial
    117. Overview
    118. Products Offered
    119. Key
    120. Developments
    121. SWOT Analysis
    122. Key
    123. Strategies
    124. GSK
    125. Financial
    126. Overview
    127. Products Offered
    128. Key
    129. Developments
    130. SWOT Analysis
    131. Key
    132. Strategies
    133. Teva Pharmaceuticals
    134. Financial
    135. Overview
    136. Products Offered
    137. Key
    138. Developments
    139. SWOT Analysis
    140. Key
    141. Strategies
    142. Otsuka
    143. Financial
    144. Overview
    145. Products Offered
    146. Key
    147. Developments
    148. SWOT Analysis
    149. Key
    150. Strategies
    151. Servier
    152. Financial
    153. Overview
    154. Products Offered
    155. Key
    156. Developments
    157. SWOT Analysis
    158. Key
    159. Strategies
    160. H Lundbeck
    161. Financial
    162. Overview
    163. Products Offered
    164. Key
    165. Developments
    166. SWOT Analysis
    167. Key
    168. Strategies
    169. Sanofi
    170. Financial
    171. Overview
    172. Products Offered
    173. Key
    174. Developments
    175. SWOT Analysis
    176. Key
    177. Strategies
    178. AstraZeneca
    179. Financial
    180. Overview
    181. Products Offered
    182. Key
    183. Developments
    184. SWOT Analysis
    185. Key
    186. Strategies
    187. Roche
    188. Financial
    189. Overview
    190. Products Offered
    191. Key
    192. Developments
    193. SWOT Analysis
    194. Key
    195. Strategies
    196. Almirall
    197. Financial
    198. Overview
    199. Products Offered
    200. Key
    201. Developments
    202. SWOT Analysis
    203. Key
    204. Strategies
    205. Bristol Myers Squibb
    206. Financial
    207. Overview
    208. Products Offered
    209. Key
    210. Developments
    211. SWOT Analysis
    212. Key
    213. Strategies
    214. Novartis
    215. Financial
    216. Overview
    217. Products Offered
    218. Key
    219. Developments
    220. SWOT Analysis
    221. Key
    222. Strategies
    223. Lilly
    224. Financial
    225. Overview
    226. Products Offered
    227. Key
    228. Developments
    229. SWOT Analysis
    230. Key
    231. Strategies
    232. Johnson & Johnson
    233. Financial
    234. Overview
    235. Products Offered
    236. Key
    237. Developments
    238. SWOT Analysis
    239. Key
    240. Strategies
    241. References
    242. Related
    243. Reports
    244. LIST
    245. OF ASSUMPTIONS
    246. France Depression Screening Mental Health
    247. Market SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2035 (USD Billions)
    248. France
    249. Depression Screening Mental Health Market SIZE ESTIMATES & FORECAST, BY DIAGNOSIS,
    250. 2035 (USD Billions)
    251. France Depression Screening
    252. Mental Health Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD
    253. Billions)
    254. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    255. ACQUISITION/PARTNERSHIP
    256. LIST
    257. Of figures
    258. MARKET SYNOPSIS
    259. FRANCE
    260. DEPRESSION SCREENING MENTAL HEALTH MARKET ANALYSIS BY INDICATION
    261. FRANCE
    262. DEPRESSION SCREENING MENTAL HEALTH MARKET ANALYSIS BY DIAGNOSIS
    263. FRANCE
    264. DEPRESSION SCREENING MENTAL HEALTH MARKET ANALYSIS BY END USER
    265. KEY
    266. BUYING CRITERIA OF DEPRESSION SCREENING MENTAL HEALTH MARKET
    267. RESEARCH
    268. PROCESS OF MRFR
    269. DRO ANALYSIS OF DEPRESSION SCREENING
    270. MENTAL HEALTH MARKET
    271. DRIVERS IMPACT ANALYSIS: DEPRESSION
    272. SCREENING MENTAL HEALTH MARKET
    273. RESTRAINTS IMPACT ANALYSIS:
    274. DEPRESSION SCREENING MENTAL HEALTH MARKET
    275. SUPPLY / VALUE
    276. CHAIN: DEPRESSION SCREENING MENTAL HEALTH MARKET
    277. DEPRESSION
    278. SCREENING MENTAL HEALTH MARKET, BY INDICATION, 2025 (% SHARE)
    279. DEPRESSION
    280. SCREENING MENTAL HEALTH MARKET, BY INDICATION, 2019 TO 2035 (USD Billions)
    281. DEPRESSION
    282. SCREENING MENTAL HEALTH MARKET, BY DIAGNOSIS, 2025 (% SHARE)
    283. DEPRESSION
    284. SCREENING MENTAL HEALTH MARKET, BY DIAGNOSIS, 2019 TO 2035 (USD Billions)
    285. DEPRESSION
    286. SCREENING MENTAL HEALTH MARKET, BY END USER, 2025 (% SHARE)
    287. DEPRESSION
    288. SCREENING MENTAL HEALTH MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    289. BENCHMARKING
    290. OF MAJOR COMPETITORS

    France Depression Screening Mental Health Market Segmentation

    • Depression Screening Mental Health Market By Indication (USD Million, 2019-2035)

      • Major Depressive Disorder
      • Anxiety Distress
      • Bipolar Disorder
      • Psychotic Disorders
      • Others

     

    • Depression Screening Mental Health Market By Diagnosis (USD Million, 2019-2035)

      • Psychological Tests
      • Blood Tests
      • Pharmacogenomic Testing
      • Others

     

    • Depression Screening Mental Health Market By End User (USD Million, 2019-2035)

      • Hospitals and Clinics
      • Home-based
      • Research and Academic Institutes

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027